Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Just stumbled on this list of quality stocks under $10 that Wall Street analysts are actually bullish on, which is kind of wild because most people sleep on cheap stocks. Like, everyone assumes low price = bad company, but that's not always true.
So there's Ambev trading around $2.83 - sounds like a penny stock but it's got a $46 billion market cap and analysts see 17% upside. Revenue growth is solid at 15.3%. Then there's Navitas, a semiconductor play up 91% this year, trading under $10 with a unanimous strong buy rating and potential 26% upside.
Gerdau caught my attention too - largest long steel producer in the Americas, trading near $5, analysts targeting $6.26. Posted $15.71B in revenue last year despite global headwinds.
Other picks on the list: Super Group (gaming/betting angle), Hello Group from China (social networking, interesting China reopening play), Arhaus (home furnishings, risky but analysts love it), and AbCellera (biotech, unanimous strong buy with insane 311% upside potential but down 24% YTD).
The thing is, these blue chip quality stocks under $10 aren't getting the attention they should. Most traders only look at expensive names. But if you dig into the fundamentals - cash positions, margins, growth rates - some of these actually check boxes. Obviously do your own research though, especially on the riskier biotech and China plays. Anyone else looking at any of these?